### NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

# **Review Proposal Project**

Technology Appraisal guidance no. 145; Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck

# Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Merck Serono (cetuximab)	Board of Community Health Councils in Wales
Patient/carer groups	British National Formulary
Afiya Trust	Care Quality Commission
Black Health Agency	Commissioning Support Appraisals
CANCERactive	Service
Cancer Black Care	Department of Health, Social Services
Cancer Equality	and Public Safety for Northern Ireland
Cancer Laryngectomee Trust	Healthcare Improvement Scotland
Cancer 52	Medicines and Healthcare products
Changing Faces	Regulatory Agency
Chinese National Healthy Living	National Association for Primary Care
Centre	National Pharmacy Association
Counsel and Care	NHS Alliance
Equalities National Council	NHS Commercial Medicines Unit
Get A-Head	NHS Confederation
Helen Rollason Heal Cancer Charity	Public Health Wales NHS Trust
Let's Face it	Scottish Medicines Consortium
Macmillan Cancer Support	
Maggie's Centres	Possible comparator manufacturers
Marie Curie Cancer Care	None
Mouth Cancer Foundation	Delevent recesses areas
Muslim Council of Britain	Relevant research groups
Muslim Health Network	Institute of Cancer Research
National Association Of	Head and Neck Cancer Research Trust     MRC Clinical Trials Unit
Laryngectomee Clubs	MRC Clinical Trials Unit     National Consent Research Institute
Rarer Cancers Foundation	National Cancer Research Institute
South Asian Health Foundation	National Cancer Research Network
Specialised Healthcare Alliance	National Institute for Health Research
	Research Institute for the Care of the

National Institute for Health and Clinical Excellence

Technology Appraisal guidance no. 145; Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck

Issue date: April 2011 Page 1 of 4

Consultees	Commentators (no right to submit or appeal)
<ul> <li>Sue Ryder Care</li> <li>Tenovus</li> <li>Professional groups</li> <li>Association of Cancer Physicians</li> <li>Association of Surgeons of Great Britain and Ireland</li> <li>British Association of Head and Neck Oncologists</li> <li>British Association of Head and Neck Oncology Nurses</li> <li>British Association of Oral and Maxillofacial Surgeons</li> <li>British Association of Otorhinolaryngologists</li> <li>British Association of Services for the Elderly</li> <li>British Association of Surgical Oncology</li> <li>British Dental Health Foundation</li> <li>British Geriatrics Society</li> <li>British Institute of Radiology</li> <li>British Psychosocial Oncology Society</li> <li>Cancer Network Pharmacists Forum</li> <li>Cancer Research UK</li> <li>Royal College of Anaesthetists</li> <li>Royal College of General Practitioners</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Physicians</li> <li>Royal College of Surgeons</li> <li>Royal College of Surgeons</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiology Nursing Society</li> <li>United Kingdom Oncology Nursing Society</li> </ul>	Elderly  Assessment Group  Assessment Group tbc  National Institute for Health Research Health Technology Assessment Programme  Associated Guideline Groups  National Collaborating Centre for Cancer  Associated Public Health Groups  none

National Institute for Health and Clinical Excellence

Technology Appraisal guidance no. 145; Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Issue date: April 2011

Page

Page 2 of 4

Consultees	Commentators (no right to submit or appeal)
<u>Others</u>	
Department of Health	
NHS Cornwall and the Isles of Scilly	
NHS Redcar and Cleveland	
Welsh Assembly Government	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

National Institute for Health and Clinical Excellence
Technology Appraisal guidance no. 145; Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Issue date: April 2011
Page 3 of 4

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

### Assessment Group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute)

Non manufacturer consultees are invited to submit statements relevant to the group they are representing.